摘要
目的为了检测ＴＰＯ的体内活性及其对血小板减少的治疗作用，寻找用以治疗辐射及化学药物等所致骨髓损伤造成的血小板减少与缺乏，缓解临床上的出血症状，降低死亡率的一种新途径。方法本实验应用基因工程的方法重组了人的ＴＰＯ，取昆明种正常雄性，经一次５．０Ｇｙ６０Ｃｏγ射线全身照射小白鼠为动物模型，通过对外周血血象的观察，及小鼠骨髓造血祖细胞培养的检测，研究了ｒｈＴＰＯ在体内对６０Ｃｏ全身照射处理小鼠的造血系统的影响。结果实验表明，ｒｈＴＰＯ能够减轻照射对小鼠外周血血小板及骨髓造血祖细胞中巨核系祖细胞的影响，并有促进其早期恢复的作用，且这种作用是量效相关的。结论提示，ＴＰＯ是巨核细胞系统较特异的正调控因子，具有促进巨核细胞增殖发育和刺激血小板生成的作用，是临床治疗骨髓组织损伤引起的血小板减少和缺乏及贫血的有希望的生物治疗药物。
Objective\ Thromboietin, a major physiological regulator of megakaryocytopoiesis, has potent effects on megakaryocytopoiesis. With a view to finding a new therapeutic modality for bone marrow injury induced thrombocytopenia, we studied the biological activity of rhTPO in vivo. Methods\ We recombined hTPO by means of RT PCR and eukaryotic expression. The rhPTO was administered to 5.0Gy 60 Co γ ray irradiated male mice, once per day for 20 consecutive days. Peripheral blood counts were monitored and bone marrow was assayed for clonogenic activity. Results\ Circulating platelet counts and CFU-MK of the rhTPO treated mice increased significantly in contrast with the control group. Conclusion\ These results show that rhTPO can restore platelets and CFU MK of irradiated mice in vivo. Clearly, our growing understanding of the biology of TPO will lead to important new insights into megakaryopoiesis and to improvement in clinical treatment of bone marrow failure.
出处
《中华放射医学与防护杂志》
CAS
CSCD
北大核心
1997年第3期151-154,共4页
Chinese Journal of Radiological Medicine and Protection
